Clinical trials: insulin glargine
Diabetes Mellitus
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
Several studies have shown that high blood sugar (glucose) levels are associated with diseases caused by diabetes. Controlling the glucose may prevent these complications.
- Trial name
- NCT01240200
- Testing
- Glargine, glargine via insulin pen
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Emory University
Diabetes Mellitus
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
- Trial name
- NCT01910194
- Testing
- Luyxumia versus Lantus
- Where
- 2 sites in Germany
- Volunteers
- 39 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes, Diabetes Mellitus, Type 2
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve…
- Trial name
- DUAL™ VIII (NCT02501161)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 143 sites in United States, Argentina and 14 more
- Volunteers
- 1,012 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.
- Trial name
- INSTRIDE 1 (NCT02227862)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 162 sites in United States, Canada and 9 more
- Volunteers
- 558 people
- Sponsor
- Mylan Inc.
Diabetes Mellitus, Type 1, Type 1 Diabetes
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g.
- Trial name
- HumAn-1 (NCT05614089)
- Testing
- Insulin Glargine, NPH or premixed 70/30 (human insulin)
- Where
- 3 sites in Bangladesh, Tanzania
- Volunteers
- 400 people
- Sponsor
- Jing Luo
Type 2 Diabetes Mellitus
Effects of Metformin in Heart Failure Patients
Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety.
- Trial name
- NCT02694289
- Testing
- Metformin, Subcutaneous (sliding scale) Insulin
- Sponsor
- Maya Guglin
Type 1 Diabetes
Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes
The objectives of the study are: 1) to evaluate the effects of moderate exercise on SG evolution without insulin dose modification in patients with T1D under continuous subcutaneous insulin infusion (CSII) and multiple daily…
- Trial name
- TREAD-DIAB (NCT02824510)
- Testing
- Algorithmic changes in insulin therapy., Treadmill exercises, Insulin aspart, glargine and detemir
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Diabetes Mellitus, Type 2
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
Primary Objective: To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change Secondary Objectives: To demonstrate superiority of Toujeo versus…
- Trial name
- Reach-Control (NCT02967224)
- Testing
- insulin glargine (U300), insulin glargine (U100), NPH insulin
- Where
- 128 sites in Brazil, France and 5 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study in Adults With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
- Trial name
- ELEMENT 2 (NCT01421459)
- Testing
- LY2963016, Lantus, OAMs
- Where
- 62 sites in United States, Czechia and 10 more
- Volunteers
- 759 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin.
- Trial name
- NCT05596747
- Testing
- LY3209590, Insulin Glargine
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
Primary objective: To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients Secondary objectives: To assess the forced titration on physician and patient satisfaction To evaluate…
- Trial name
- LANTIT (NCT00701831)
- Testing
- Insulin glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral…
- Trial name
- NCT00437112
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 19 sites in United States, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control
We designed this prospective, randomized control study to compare the benefits between the insulin therapy and OADs after correction of the glucose toxicity with a short period of intensive insulin therapy.
- Trial name
- NCT00506194
- Testing
- Insulin, OAD
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Diabetes Mellitus, Type 2
Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
Study Primary Objectives: To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral…
- Trial name
- NCT01336751
- Testing
- Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Sanofi
Diabetes Mellitus
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
The purpose of this research study is to test the safety and efficacy of a drug called saxagliptin (Onglyza) for treatment of type 2 diabetes in non-critically ill hospitalized patients who have an HbA1c of 7.5 or lower, on 1 or…
- Trial name
- NCT02182895
- Testing
- Saxagliptin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Brigham and Women's Hospital
Type 1 Diabetes
Health Care for Type 1 Diabetes in Developing World
This study is a pilot 2-armed, randomized, open label, clinical trial evaluating the effectiveness of a basal approach to diabetes management as compared to the current standard treatment (regular/NPH).
- Trial name
- NCT01424046
- Testing
- basal insulin glargine, standard therapy
- Where
- Rwanda
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Type 1 Diabetes
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients.
- Trial name
- GLIDING (NCT04623086)
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Washington
Type 1 Diabetes Mellitus
Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)
Primary Objective: To establish initial safety/tolerability and pharmacodynamic and pharmacokinetic profiles of four formulations of SAR161271 in patients with T1DM.
- Trial name
- NCT01053728
- Testing
- SAR161271, Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Primary Objective: 6 To assess the efficacy of insulin glargine given once daily (QD) on glycosylated hemoglobin (HbA1c) levels over a period of 24 weeks in children with type 1 diabetes mellitus (T1DM) aged at least 6 years to…
- Trial name
- Lantus-P-CN (NCT01223131)
- Testing
- Insulin glargine (HOE901), NPH insulin
- Where
- 10 sites in China
- Volunteers
- 162 people
- Sponsor
- Sanofi
Type 2 Diabetes
The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
The purpose of this study, which is being conducted at 100 centers throughout the United States, is to determine whether Lantus, a long-acting insulin injection, either alone or in combination with metformin, is effective in…
- Trial name
- NCT00366301
- Testing
- Insulin glargine injection, metformin
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Brigham and Women's Hospital